Summary

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may reduce excision repair cross-complementing group 1 (ERCC1) gene expression, potentially enhancing sensitivity to platinum-based chemotherapy in patients with non—small cell lung cancer (NSCLC), according to results from a poster presented by Cheong et al. [Cheong HT et al. J Thorac Oncol 2014].